Closely held pharmaceutical maker Stiefel Laboratories is considering selling itself in a deal that could be worth several billion dollars, and the company has drawn interest from Johnson & Johnson ( JNJ), Novartis ( NVS) and GlaxoSmithKline ( GSK), a report says. Stiefel, which makes anti-itch creams, acne treatments and other dermatological remedies, is hoping to sell itself for about $3 billion to $4 billion, the Wall Street Journal reports, citing people familiar with the matter. A Stiefel spokeswoman said the company's board hasn't decided to sell the company and hasn't received any offers. "Like any business, if we received an offer it would be carefully considered," the spokeswoman said in an email to the Journal. Stiefel has been controlled for more than 160 years by the founding Stiefel family, according to the newspaper. Blackstone Group ( BX), a private-equity firm, owns a substantial minority stake. Stiefel has annual revenue of about $1 billion, one person familiar with the company said, the Journal reports. The newspaper reports Stiefel has entertained offers in the past, but the recent spate of drug deals has renewed interest in the company. Earlier this month, Merck ( MRK) made an offer to buy rival Schering-Plough ( SGP ) for $41 billion, and Swiss pharmaceutical company Roche announced that it agreed to buy the rest of biotechnology pioneer Genentech ( DNA). In January, Pfizer ( PFE) announced a deal to buy Wyeth ( WYE) for cash, stock and debt valued then at $68 billion.